 F-652 is a recombinant fusion protein containing human interleukin 22 IL-22 and human Immunoglobulin G2 IgG2-Fc produced in CHO cells in serum-free culture. F-652 under development is intended to treat patients with graft vs host disease GvHD after bone marrow transplantation, and acute alcoholic hepatitis AAH, a severe form of alcoholic liver disease ALD. Both GvHD and AAH are diseases with unmet medical need. The current investigational new drug IND application is to conduct a phase Ia clinical study in GvHD patients to evaluate the safety and pharmacokinetic profile, and biomarkers of F-652 treatment by intravenous infusion IV. 